Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines, Inc. (RVMD) Form 144 discloses a proposed sale of 2,131 shares of common stock through ETRADE with an aggregate market value of $99,198.05, with an approximate sale date of 09/15/2025 on NASDAQ. The securities originated from restricted stock unit grants received from the issuer on 05/01/2023 (1,253 shares), 03/01/2024 (412 shares) and 03/01/2025 (466 shares), each noted as payment for services rendered. The filing also reports a prior sale by the same person of 2,173 shares on 06/16/2025 generating $86,550.59. The filer certifies no undisclosed material adverse information is known.
Revolution Medicines, Inc. (RVMD) Form 144 summary: The filing notifies a proposed sale of 5,296 shares of common stock with an aggregate market value of $246,528.80. The company reports 186,933,190 shares outstanding. The shares to be sold were granted as restricted stock units on 03/01/2022 (1,232), 03/01/2023 (1,270), 03/01/2024 (1,632) and 03/01/2025 (1,162), each described as payment for services.
The filing also discloses past sales by the same person over the past three months totaling 129,289 shares for aggregate gross proceeds of $5,728,585.16. The listed broker for the proposed sale is ETRADE and the approximate sale date is 09/15/2025 on NASDAQ. The filer attests there is no undisclosed material adverse information.
Revolution Medicines, Inc. (RVMD) filing a Form 144 notifies the SEC of a proposed sale of 4,712 shares of common stock, with an aggregate market value of $219,343.60, expected to be sold around 09/15/2025 on NASDAQ. The shares were received as restricted stock unit grants issued on 03/01 of 2022, 2023, 2024 and 2025 totaling 4,712 shares acquired for services rendered. The filer also reported a recent sale on 06/16/2025 of 3,510 shares for gross proceeds of $139,803.30. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 trading plan disclosure if applicable.
Revolution Medicines (RVMD) Form 144 reports a proposed sale of 13,236 shares of common stock through ETRADE with an aggregate market value of $616,135.80, scheduled approximately on 09/15/2025 and to be executed on Nasdaq. The filing lists four prior restricted stock unit grants acquired on 03/01/2022, 03/01/2023, 03/01/2024 and 03/01/2025 totaling 13,136 shares received for services. It also discloses a sale by the same person on 06/16/2025 of 13,496 shares for gross proceeds of $537,545.68. The filer certifies no undisclosed material information.
Revolution Medicines (RVMD) filed a Form 144 notice for the proposed sale of 1,842 shares of common stock to be executed through ETRADE with an aggregate market value of $85,745.10. The filing shows the shares were acquired as restricted stock unit grants between 03/01/2022 and 03/01/2025 in five tranches totaling 1,842 shares, with the planned approximate sale date of 09/15/2025 on NASDAQ. The filer also reported two prior sales in the past three months by Jeff Cislini: 1,878 shares on 06/16/2025 for $74,800.74 and 1,912 shares on 06/20/2025 for $75,735.85. The filing lists total shares outstanding as 186,933,190, indicating the position is small relative to the company’s outstanding stock.
Insider transactions by Stephen Michael Kelsey at Revolution Medicines (RVMD) show option exercises and systematic sales under a 10b5-1 plan adopted February 28, 2025. On September 11 and September 15, 2025, the reporting person acquired stock options exercisable at $4.73 (100,000 and 25,000 options) and sold portions of common stock in multiple trades at weighted average sale prices reported as $43.5771, $44.4847, $45.9175 and $46.9302. The filing reports beneficial ownership of 289,414 shares of common stock (direct) following the transactions and includes restricted stock units of 94,426 within holdings. The transactions were executed pursuant to the 10b5-1 plan and were signed by an attorney-in-fact on behalf of the reporting person.
Revolution Medicines, Inc. (RVMD) notice reports a proposed sale under Rule 144 of 150,000 common shares through Morgan Stanley Smith Barney. The filing shows the shares were acquired and will be sold on 09/11/2025 via exercise of stock options, with cash payment at exercise. The filing lists an aggregate market value of $6,067,500 for the shares and reports 186,933,190 shares outstanding, implying the 150,000-share block represents about 0.08% of outstanding common stock. The filer also disclosed a prior sale on 06/16/2025 of 4,289 shares for gross proceeds of $170,830.87. The notice contains broker details and the filer’s signature attestations required under Rule 144.
Revolution Medicines (RVMD) reported clinical updates for daraxonrasib in RAS-mutant pancreatic ductal adenocarcinoma (PDAC). Safety data as of a June 30, 2025 second-line cutoff and a July 28, 2025 first-line cutoff show the most common treatment-related adverse events were rash and gastrointestinal toxicities. Results from the RMC-6236-001 and RMC-GI-102 studies support the company’s plan to start RASolute 303, a global randomized Phase 3 trial comparing daraxonrasib monotherapy and daraxonrasib plus GnP against GnP alone in first-line metastatic RAS-mutant PDAC.
The filing reiterates standard forward-looking risk disclosures about clinical development, regulatory review, manufacturing, intellectual property, third-party reliance, capital sufficiency, and geopolitical or pandemic effects.
Revolution Medicines CFO Jack Anders reported multiple transactions under a 10b5-1 plan on September 2-3, 2025. The filings show option exercises and open-market sales and purchases: Mr. Anders exercised stock options at strike prices of $2.68, $4.73 and $17 and acquired 9,200 shares through option exercises and purchase transactions at prices between $2.68 and $17. He sold a total of 10,000 shares in multiple trades at weighted-average sale prices of approximately $40.02 and $40.1742. After these transactions he beneficially owned 113,314 shares (which include 54,213 RSUs) and held stock options exercisable into 15,418 shares. The transactions were made pursuant to a 10b5-1 trading plan adopted December 16, 2024.
Form 144 notice for Revolution Medicines, Inc. (RVMD) reporting a proposed sale of 10,000 common shares acquired and to be sold on 09/02/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the aggregate market value of the shares at filing is $379,700.00. The filing states the issuer has 186,933,190 shares outstanding. The seller previously disposed of 2,170 common shares on 06/16/2025 for $86,431.10. The filer affirms no undisclosed material adverse information and includes standard Rule 10b5-1/attestation language.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
